Semaglutide before and after: real results from clinical trials

Most semaglutide before and after claims online come from individual anecdotes. The actual data is more useful. Across five large clinical trials (the STEP program), semaglutide 2.4 mg produced average weight loss of 14.9% to 17.4% of body weight over 68 weeks in people without type 2 diabetes [1]. For someone starting at 230 pounds, that’s roughly 34 to 40 pounds.

This page breaks down what the clinical trials actually found, week by week, so you know what to expect before you start.

Results snapshot

Metric	Result
Average weight loss (STEP 1)	14.9% of body weight at 68 weeks
Participants losing ≥10%	69% to 79% across trials
Participants losing ≥15%	51% to 64% across trials
Time to maximum dose	16 weeks (dose escalation)
Duration studied	Up to 104 weeks (STEP 5)
Trial size (STEP 1)	1,961 participants

What to expect: a week-by-week timeline

Weeks 1 through 4: dose escalation begins

Semaglutide starts at 0.25 mg weekly and increases every four weeks. During the first month, most people notice reduced appetite and some early GI side effects. Weight loss is modest at this stage, typically 1% to 2% of body weight. The low starting dose exists specifically to let your body adjust [2].

You might feel less hungry between meals. Some people describe it as their “food noise” quieting down. Nausea is the most common side effect in this window.

Weeks 4 through 12: steady progress

By week 8, the dose has increased to 1.0 mg. Weight loss picks up to roughly 2% of body weight per month. Most of the GI side effects that people experience show up during dose increases and then fade [3]. In the STEP 1 trial, participants were losing weight at a consistent clip during this period, with the curve steepening as the dose went up.

This is also when changes in body composition become noticeable. Clothes fit differently before the scale moves as much as you’d expect.

Weeks 12 through 24: the steepest phase

At week 16, participants reach the full 2.4 mg dose. This is where the most visible changes happen. In STEP 1, participants had lost approximately 10% of body weight by the six-month mark [1]. That’s 23 pounds on a 230-pound person.

If you’re comparing yourself to what you see in semaglutide vs tirzepatide discussions online, keep in mind that individual results vary widely. Some people respond faster, some slower. The trial data represents averages across thousands of participants.

Weeks 24 through 48: continued loss, slower pace

Weight loss continues but the monthly rate slows to about 1% of body weight per month [4]. This isn’t a plateau. It’s the normal deceleration that happens as your body adjusts to a lower weight. STEP 5, which tracked participants for two full years, confirmed that weight loss continued beyond the six-month mark [5].

During this period, secondary health markers also improve. Blood pressure, waist circumference, and inflammatory markers all moved in favorable directions across the STEP trials [1].

Weeks 48 through 68: approaching maximum results

By week 68, STEP 1 participants on semaglutide had lost an average of 14.9% of body weight, compared to 2.4% in the placebo group [1]. That’s a 12.4 percentage point difference attributable to the medication itself, beyond what diet and exercise alone achieved.

In STEP 4, participants who continued semaglutide after an initial 20-week run-in lost 17.4% total, while those switched to placebo regained weight [6]. That trial answered an important question: stopping semaglutide leads to weight regain.

Clinical trial results by the numbers

STEP 1: the flagship trial

Published in the New England Journal of Medicine, STEP 1 enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related condition) but without type 2 diabetes. Participants received semaglutide 2.4 mg or placebo alongside lifestyle intervention [1].

Results at 68 weeks:

• Mean weight loss: 14.9% with semaglutide vs. 2.4% with placebo
• 86.4% of semaglutide participants lost ≥5% body weight (vs. 31.5% placebo)
• 69.1% lost ≥10% (vs. 12% placebo)
• 50.5% lost ≥15% (vs. 4.9% placebo)
• 32.0% lost ≥20% (vs. 1.7% placebo)

One in three participants on semaglutide lost 20% or more of their body weight. For context, bariatric surgery typically produces 25% to 30% weight loss.

STEP 2: participants with type 2 diabetes

STEP 2 focused on adults with overweight or obesity who also had type 2 diabetes. Weight loss was lower, which is consistent across all GLP-1 medications in diabetic populations. Mean weight loss was 9.6% with semaglutide vs. 3.4% with placebo at 68 weeks [7].

This matters because many people searching for semaglutide online prescriptions have type 2 diabetes. If that’s you, expect results closer to the STEP 2 numbers.

STEP 3: semaglutide plus intensive behavioral therapy

When combined with a structured behavioral program (including an initial low-calorie diet phase), semaglutide produced 16.0% mean weight loss at 68 weeks [8]. This trial suggests that combining medication with structured lifestyle changes produces better results than medication alone.

STEP 4: what happens when you stop

This trial design was clever. Everyone took semaglutide for 20 weeks. Then half continued and half switched to placebo. Those who continued lost 17.4% total by week 68. Those who stopped regained about two-thirds of the weight they’d lost during the run-in period [6].

The takeaway is straightforward: semaglutide works while you take it. Weight management with GLP-1 medications is a long-term commitment, not a short course of treatment.

STEP 5: two-year data

STEP 5 followed participants for 104 weeks, the longest published trial. Mean weight loss was 15.2% with semaglutide versus 2.6% with placebo [5]. Weight loss was maintained through the second year, confirming that the results hold up over time.

Side effects during treatment

GI side effects are the most common reason people consider stopping. Here’s what the pooled STEP trial data actually shows [3]:

Side effect	Semaglutide	Placebo
Nausea	43.9%	16.1%
Diarrhea	29.7%	15.9%
Vomiting	24.5%	6.3%
Constipation	24.2%	11.1%

Those numbers look high, but context matters. 99.5% of GI side effects were classified as non-serious. Most were mild to moderate and occurred during dose escalation, fading as the body adjusted. In STEP 1, only 7% of semaglutide participants discontinued due to adverse events, compared to 3.1% on placebo [1].

The nausea is real, but it’s usually temporary. Eating smaller meals and avoiding fatty or fried foods during dose increases helps most people manage it.

Factors that affect your results

Not everyone loses 15%. Several factors influence individual outcomes:

Starting BMI. People with higher starting BMIs tend to lose more absolute weight but sometimes a smaller percentage. The STEP trials enrolled participants with BMIs ranging from 27 to well above 40.

Type 2 diabetes. As STEP 2 showed, people with T2D lose about 5 percentage points less than those without. The metabolic differences in diabetes affect how the body responds to GLP-1 medications.

Dose tolerance. Some people can’t reach the full 2.4 mg dose due to side effects. Lower doses produce less weight loss. If you need to buy semaglutide online through a compounding pharmacy, your provider should still follow the standard escalation protocol.

Diet and exercise. STEP 3 showed that adding structured behavioral therapy on top of semaglutide boosted results from ~15% to 16%. The medication reduces appetite, but what you eat and how you move still matter.

Genetics. Some people are GLP-1 “super-responders” and others see more modest effects. This isn’t fully understood yet, but it’s real. About 14% of STEP 1 participants lost less than 5% of body weight on semaglutide [1].

Tips for best results

The STEP trials all included lifestyle intervention alongside medication. Here’s what the evidence supports:

Eat a high-protein diet. Semaglutide reduces appetite, but it doesn’t choose what you eat. Protein helps preserve lean muscle mass during weight loss, which matters for long-term metabolic health. A target of 1.2 to 1.6 grams per kilogram of body weight per day is a reasonable starting point.

Stay physically active. The STEP trials included lifestyle counseling with activity targets. Resistance training specifically helps counteract the muscle loss that can accompany GLP-1 treatment. Aim for 150 minutes of moderate activity per week plus two resistance sessions.

Follow the dose escalation schedule. Jumping to higher doses too quickly increases side effects without improving outcomes. The 16-week ramp was designed for a reason.

Track your progress beyond the scale. Waist circumference, how your clothes fit, energy levels, and blood work all reflect real changes that the scale misses.

FAQ

How much weight can I lose on semaglutide?▼

In the STEP 1 trial, the average was 14.9% of body weight at 68 weeks. About half of participants lost 15% or more, and one in three lost 20% or more [1]. Individual results vary based on starting weight, diabetes status, diet, and activity level.

How fast will I see results with semaglutide?▼

Most people notice appetite changes within the first week or two. Measurable weight loss typically appears within the first month. The rate is approximately 2% of body weight per month for the first six months, then about 1% per month after that [4].

Will I regain weight if I stop semaglutide?▼

STEP 4 showed that participants who stopped semaglutide after 20 weeks regained about two-thirds of their lost weight over the following 48 weeks [6]. Current evidence supports semaglutide as a long-term treatment, not a short-term fix.

What’s the difference between semaglutide and Wegovy?▼

Wegovy is the brand name for semaglutide 2.4 mg approved specifically for weight management. Ozempic is semaglutide at lower doses (0.5 mg to 2.0 mg) approved for type 2 diabetes. Compounded semaglutide is the same molecule prepared by compounding pharmacies, typically at lower cost. Learn more about compounded semaglutide safety.

Does semaglutide work for people with type 2 diabetes?▼

Yes, but expect less weight loss. STEP 2 found an average of 9.6% weight loss in participants with T2D, compared to 14.9% in STEP 1 (without T2D) [7]. The medication still improves blood sugar control significantly.

How does semaglutide compare to tirzepatide?▼

A head-to-head trial found tirzepatide produced 20.2% weight loss versus 13.7% for semaglutide at 72 weeks [9]. Both are effective, but tirzepatide shows a statistical advantage. See our full semaglutide vs tirzepatide comparison or check tirzepatide before and after results.

Is semaglutide safe long-term?▼

STEP 5 followed participants for two years with a consistent safety profile. The most common side effects remain GI-related and are typically mild to moderate [5]. Ongoing post-marketing surveillance continues.

How do I get started with semaglutide?▼

You need a prescription from a licensed provider. An online weight loss doctor can evaluate whether you qualify based on your BMI, health history, and goals.

Ready to see your own results? Start your free evaluation at PURE →

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183

2. Novo Nordisk. Wegovy (semaglutide) prescribing information. 2021.

3. Wharton S, Calanna S, Davies M, et al. Gastrointestinal tolerability of once-weekly semaglutide 2.4 mg in adults with overweight or obesity. Diabetes Obes Metab. 2022;24(1):94-105. doi:10.1111/dom.14551

4. Rivas Medical Weight Loss. How fast does semaglutide work? Results by week. 2026.

5. Garvey WT, Batterham RL, Bhatt DL, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28:2083-2091.

6. Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial. JAMA. 2021;325(14):1414-1425. doi:10.1001/jama.2021.3224

7. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.

8. Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021;325(14):1403-1413.

9. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity. N Engl J Med. 2025. doi:10.1056/NEJMoa2416394